What is the Impact Factor of Cancer Gene Therapy?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Cancer Gene Therapy is 6.40, ranking in quartile Q1 of Web of Science (SCIE).

Is Cancer Gene Therapy indexed in Web of Science or Scopus?

Yes, Cancer Gene Therapy is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.749 (Q1) and an H-index of 103.

Who publishes Cancer Gene Therapy and what is the Article Processing Charge (APC)?

Cancer Gene Therapy is published by Springer Nature. The estimated Article Processing Charge (APC) is approximately $3,590 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Cancer Gene Therapy?

The official ISO-4 abbreviation of Cancer Gene Therapy is "CANCER GENE THER" with common acronym "cgt". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q1SCImago #1,850Hybrid

Cancer Gene Therapy

Acronym:cgt

•

Abbreviation (ISO):CANCER GENE THER

•

Identifier (ISSN):0929-1903(Print)/1476-5500(Online)

•

Publisher:Springer Nature

Official Website Submission Portal Compare

Clarivate IF (2026)

6.4↑ +1.4

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Cancer Gene Therapy

WoS Q1

Annual Impact Factor Metric

Current (2026):6.4

Scopus SJR & RankScopus Q1

1.749

#1,850

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

103

103 papers with at least that number of citations each

WoS: SCIE / JCRQ1

Self-Citation Rate2.1%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

112articles/year

44.92% Gold OA•85.52% Original Research

Aims & Scope

Cancer Gene Therapy is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. The journal publishes original laboratory and clinical research papers, case reports and review articles. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. Cancer Gene Therapy publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Types of articles published include original research articles; case reports; brief communications; review articles in the main fields of drug resistance/sensitivity, gene therapy, cellular therapy, tumor suppressor and anti-oncogene therapy, cytokine/tumor immunotherapy, etc.; industry perspectives; and letters to the editor.

Topics Covered (Recognized by AI)

BiologyGeneticsMedicineChemistryBiochemistryCancer ResearchInternal MedicineOncology & Cancer ResearchImmunologyMolecular BiologyImmune SystemVirologyCell BiologyPathology

Primary Research Areas

Rank72/333

IndexSCIE

Category	Index	Rank	Quartile
BIOTECHNOLOGY & APPLIED MICROBIOLOGY	JCRSCIE	27/180	Q1
GENETICS & HEREDITY	JCRSCIE	21/192	Q1
MEDICINE, RESEARCH & EXPERIMENTAL	JCRSCIE	39/191	Q1
ONCOLOGY	JCRSCIE	59/333	Q1
BIOTECHNOLOGY & APPLIED MICROBIOLOGY	JCISCIE	25/180	Q1
GENETICS & HEREDITY	JCISCIE	32/192	Q1
MEDICINE, RESEARCH & EXPERIMENTAL	JCISCIE	44/191	Q1
ONCOLOGY	JCISCIE	72/333	Q1

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF6.4

Articles / Year82

Total Citations39

2025

IF5

Articles / Year130

Total Citations507

2024

IF4.8

Articles / Year146

Total Citations2,020

2023

IF6.4

Articles / Year140

Total Citations2,084

2022

IF5.854

Articles / Year170

Total Citations3,116

Year	Impact Factor	Articles / Year	Total Citations
2026	6.4	82	39
2025	5	130	507
2024	4.8	146	2,020
2023	6.4	140	2,084
2022	5.854	170	3,116
2021	5.987	137	4,134
2020	4.534	111	4,381
2019	4.681	87	2,713
2018	4.044	61	1,935
2017	—	49	2,055
2016	—	77	3,514
2015	—	80	2,846

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #1,850Scopus Q1SCImago Profile

Scopus Coverage:1994-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular Biology

Scopus Citation Rank (SJR)Q1

1.749

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

6.07

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,590 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations2,829

3-Year Documents488

Citable Documents475

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate43.8%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Molecular BiologyQ1

Molecular MedicineQ1

Cancer ResearchQ2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 2.1%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

2区BIOTECHNOLOGY & APPLIED MICROBIOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Cancer Gene Therapy (acronym: cgt, abbr: CANCER GENE THER, ISSN: 0929-1903) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer Nature in England since 1999. The periodical holds a Journal Impact Factor (JIF) of 6.40, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 1.749 (Q1), an H-index of 103.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 112 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,590 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.